As predicted, on Day 21, the BLI of tumours treated with cocultured CD8+ T cells combined with CAR NK‐92 cells and atezolizumab or nivolumab was evidently lower than that of the tumour treated with a combination of CAR NK‐92 cells and cocultured CD8+ T cells without ICI (Figure 6A,C). The gene discussed is CD8A; the disease is neoplasm.